Benralizumab Regulates Atopic Dermatitis Through Effects on Eosinophils, Basophils and Innate Lymphoid Type 2 Cells.
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 22 Aug 2018
At a glance
- Drugs Benralizumab (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- 14 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
- 28 Jun 2018 New trial record